title: [p53 mutations and chemoresistance in oromaxillofacial squamous-cell carcinomas. The results of a molecular genetics study of p53 in metastatic oromaxillofacial tumors and an evaluation of the response to neoadjuvant chemotherapeutic treatment].
abstract: METHODS
  The authors carried out a p53 genetic research on native DNA in 15 oral-maxillofacial squamous cell carcinomas, lymph nodes metastasis, treated with neoadjuvant chemotherapy, checking the p53 "status" and the clinical response to the chemotherapeutic treatment (three 5-FU/CDDP cycles).
  
  
  RESULTS
  The authors found p53 mutations in 3/15 cases. In these cases, at post-chemo restaging, it resulted 2 progressions and 1 stability of disease. In the 12 cases with wildtype p53: 4 objective improvements and partial responses (PR), respectively, of 55% (1), 60% (1), 65% (1), 70% (1), 75% (2) and 90% (2). The 15 patients were treated then by surgery and adjuvant chemotherapy (three C-F cycles). These results seem to confirm the outcome of the researches "in vitro" and they provide first correlations between p53 mutations and chemoresistance in oral squamous cell carcinomas. The survival evaluation also, in the examined cases, shows, but with medium-term follow-up, the tendency to a poor prognosis when p53 is altered.
  
  
  CONCLUSIONS
  This research outlines the possibility, also for oral and maxillofacial tumors, to utilize, p53 as a prognostic and chemoresponse marker, useful, with the otherwise well-known prognostic factors, for the evaluation of advanced cancers, in the interests of a more suitable therapeutic protocol.
authors.affiliation: Dipartimento di Discipline Chirurgiche, Università degli Studi, L'Aquila.
authors.forename: T
authors.initials: T
authors.lastname: Cutilli
authors.forename: F
authors.initials: F
authors.lastname: Papola
authors.forename: P
authors.initials: P
authors.lastname: Di Emidio
authors.forename: P
authors.initials: P
authors.lastname: Leocata
authors.forename: A
authors.initials: A
authors.lastname: Corbacelli
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000235:genetics*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004351:Drug Resistance / Q000235:genetics; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation / Q000235:genetics*; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D000964:Antimetabolites, Antineoplastic; D016159:Tumor Suppressor Protein p53; D002945:Cisplatin; D005472:Fluorouracil
vernacular_title: Mutazioni della p53 e chemioresistenza nei carcinomi squamosi oro-maxillo-facciali. Risultati dello studio genetico molecolare della p53 in tumori oro-maxillo-facciali metastatizzati e valutazione della risposta al trattamento chemioterapico neoadiuvante.